{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:20Z","timestamp":1787020220925,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003509","name":"\u00d6rebro University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or two-dose treatment. The extended half-life, good penetration into bone and synovial fluid, and bactericidal activity against gram-positive bacteria, including those in biofilm, make dalbavancin an appealing choice for treatment of bone and joint infections in outpatient settings. However, we present a rare case of ototoxicity associated with off-label extended dalbavancin treatment of a prosthetic joint infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 55-year-old man with a prosthetic joint infection of the shoulder underwent off-label extended dalbavancin treatment, receiving a cumulative dose of 2500\u00a0mg. The patient experienced a gradual onset of hearing loss following the first dose, leading to a diagnosis of bilateral sensorineural hearing loss that persisted 1 year after dalbavancin was discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case report highlights the importance of exercising caution when administering dalbavancin beyond approved dosing guidelines, and emphasizes the need for vigilance regarding the potential for ototoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08709-8","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T12:01:42Z","timestamp":1697716902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection"],"prefix":"10.1186","volume":"23","author":[{"given":"Anna","family":"Lange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrica","family":"Thunberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"S\u00f6derquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"8709_CR1","doi-asserted-by":"publisher","first-page":"e935","DOI":"10.5435\/JAAOS-D-18-00232","volume":"27","author":"ES Paxton","year":"2019","unstructured":"Paxton ES, Green A, Krueger VS. Periprosthetic infections of the shoulder: diagnosis and management. J Am Acad Orthop Surg. 2019;27:e935\u201344. https:\/\/doi.org\/10.5435\/JAAOS-D-18-00232. Cited:in: PMID: 31008878.","journal-title":"J Am Acad Orthop Surg"},{"key":"8709_CR2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jseint.2023.03.013","volume":"7","author":"S Schick","year":"2023","unstructured":"Schick S, Elphingstone J, Murali S, Carter K, Davis W, McGwin G, Evely T, Ponce B, Momaya A, Brabston E. The incidence of shoulder arthroplasty infection presents a substantial economic burden in the United States: a predictive model. JSES Int. 2023;7:636\u201341. https:\/\/doi.org\/10.1016\/j.jseint.2023.03.013. Cited:in: PMID: 37426907.","journal-title":"JSES Int"},{"key":"8709_CR3","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1097\/CORR.0000000000001838","volume":"479","author":"P Wildeman","year":"2021","unstructured":"Wildeman P, Rolfson O, S\u00f6derquist B, Wretenberg P, Lindgren V. What are the long-term outcomes of mortality, quality of life, and hip function after prosthetic joint infection of the hip? A 10-year follow-up from Sweden. Clin Orthop Relat Res. 2021;479:2203\u201313. https:\/\/doi.org\/10.1097\/CORR.0000000000001838.","journal-title":"Clin Orthop Relat Res"},{"key":"8709_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0140-6736(14)61798-0","volume":"387","author":"BH Kapadia","year":"2016","unstructured":"Kapadia BH, Berg RA, Daley JA, Fritz J, Bhave A, Mont MA. Periprosthetic joint infection. Lancet. 2016;387:386\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(14)61798-0.","journal-title":"Lancet"},{"key":"8709_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1128\/CMR.00092-13","volume":"27","author":"Y Achermann","year":"2014","unstructured":"Achermann Y, Goldstein EJC, Coenye T, Shirtliff ME. Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen. Clin Microbiol Rev. 2014;27:419\u201340. https:\/\/doi.org\/10.1128\/CMR.00092-13.","journal-title":"Clin Microbiol Rev"},{"key":"8709_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/17585732211019010","volume":"14","author":"T Paziuk","year":"2022","unstructured":"Paziuk T, Cox RM, Gutman MJ, Rondon AJ, Nicholson T, Belden K, Namdari S. Periprosthetic joint infections of the shoulder: a 10-year retrospective analysis outlining the heterogeneity among these patients. Shoulder Elbow. 2022;14:598\u2013605. https:\/\/doi.org\/10.1177\/17585732211019010. Cited:in: PMID: 36479014.","journal-title":"Shoulder Elbow"},{"key":"8709_CR7","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1017\/S0950268818001437","volume":"146","author":"J Lourtet-Hasco\u00ebt","year":"2018","unstructured":"Lourtet-Hasco\u00ebt J, F\u00e9lic\u00e9 MP, Bicart-See A, Bouige A, Giordano G, Bonnet E. Species and antimicrobial susceptibility testing of coagulase-negative staphylococci in periprosthetic joint infections. Epidemiol Infect. 2018;146:1771\u20136. https:\/\/doi.org\/10.1017\/S0950268818001437. Cited:in: PMID: 29880073.","journal-title":"Epidemiol Infect"},{"key":"8709_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.diagmicrobio.2016.05.009","volume":"85","author":"J Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez J, Greenwood-Quaintance KE, Patel R. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis. 2016;85:449\u201351. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.05.009. Cited:in: PMID: 27241369.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"8709_CR9","doi-asserted-by":"publisher","first-page":"114901","DOI":"10.1016\/j.diagmicrobio.2019.114901","volume":"96","author":"V Di Pilato","year":"2020","unstructured":"Di Pilato V, Ceccherini F, Sennati S, D\u2019Agostino F, Arena F, D\u2019Atanasio N, Di Giorgio FP, Tongiani S, Pallecchi L, Rossolini GM. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times. Diagn Microbiol Infect Dis. 2020;96:114901. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.114901.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"8709_CR10","unstructured":"Dalvance\u00ae [package insert]. Chicago: Durata Therapeutics Inc; 2014. http:\/\/content.stockpr.com\/duratatherapeutics\/files\/docs\/Dalvance+APPROVED+USPI.PDF. Accessed 2 Sept 2023."},{"key":"8709_CR11","doi-asserted-by":"publisher","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","volume":"6","author":"U Rappo","year":"2019","unstructured":"Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, Suen A, Mas Casullo V, Melnick D, Miceli R, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019;6:ofy331. https:\/\/doi.org\/10.1093\/ofid\/ofy331.","journal-title":"Open Forum Infect Dis"},{"key":"8709_CR12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/antibiotics10060656","volume":"10","author":"L Buz\u00f3n-Mart\u00edn","year":"2021","unstructured":"Buz\u00f3n-Mart\u00edn L, Zollner-Schwetz I, Tobudic S, Cercenado E, Lora-Tamayo J. Dalbavancin for the treatment of prosthetic joint infections: a narrative review. Antibiotics. 2021;10:656. https:\/\/doi.org\/10.3390\/antibiotics10060656.","journal-title":"Antibiotics"},{"key":"8709_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","volume":"81","author":"S Wunsch","year":"2019","unstructured":"Wunsch S, Krause R, Valentin T, Prattes J, Janata O, Lenger A, Bellmann-Weiler R, Weiss G, Zollner-Schwetz I. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210\u20134. https:\/\/doi.org\/10.1016\/j.ijid.2019.02.013.","journal-title":"Int J Infect Dis"},{"key":"8709_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/TCRM.S271445","volume":"17","author":"O Simonetti","year":"2021","unstructured":"Simonetti O, Rizzetto G, Molinelli E, Cirioni O, Offidani A. Review: a safety profile of dalbavancin for on- and off-label utilization. TCRM. 2021;17:223\u201332. https:\/\/doi.org\/10.2147\/TCRM.S271445.","journal-title":"TCRM"},{"key":"8709_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/14740338.2022.2122437","volume":"21","author":"E Righi","year":"2022","unstructured":"Righi E, Visentin A, Meroi M, Carrara E, Tacconelli E. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation. Expert Opin Drug Saf. 2022;21:1171\u201381. https:\/\/doi.org\/10.1080\/14740338.2022.2122437.","journal-title":"Expert Opin Drug Saf"},{"key":"8709_CR16","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.2147\/DDDT.S313756","volume":"15","author":"M Gatti","year":"2021","unstructured":"Gatti M, Andreoni M, Pea F, Viale P. Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs. DDDT. 2021;15:3349\u201378. https:\/\/doi.org\/10.2147\/DDDT.S313756.","journal-title":"DDDT"},{"key":"8709_CR17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/antibiotics10091129","volume":"10","author":"L Brescini","year":"2021","unstructured":"Brescini L, Della Martera F, Morroni G, Mazzanti S, Di Pietrantonio M, Mantini P, Candelaresi B, Pallotta F, Olivieri S, Iencinella V, et al. Use of dalbavancin in skin, bone and joint infections: a real-life experience in an Italian center. Antibiotics (Basel). 2021;10:1129. https:\/\/doi.org\/10.3390\/antibiotics10091129. Cited:in: PMID: 34572711.","journal-title":"Antibiotics (Basel)"},{"key":"8709_CR18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","volume":"18","author":"F Bai","year":"2020","unstructured":"Bai F, Aldieri C, Cattelan A, Raumer F, Di Meco E, Moioli MC, Tordato F, Morelli P, Borghi F, Rizzi M, et al. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). Expert Rev Anti Infect Ther. 2020;18:1271\u20139. https:\/\/doi.org\/10.1080\/14787210.2020.1798227.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"8709_CR19","doi-asserted-by":"publisher","first-page":"dlac120","DOI":"10.1093\/jacamr\/dlac120","volume":"4","author":"L Morata","year":"2022","unstructured":"Morata L, Aguado JM, Salavert M, Pasquau J, M\u00edguez E, Mu\u00f1oz P, Rossell\u00f3 I, Almirante B. Dalbavancin in clinical practice in Spain: a 2 year retrospective study. JAC Antimicrob Resist. 2022;4:dlac120. https:\/\/doi.org\/10.1093\/jacamr\/dlac120. Cited: in:\u202f: PMID: 36570687.","journal-title":"JAC Antimicrob Resist"},{"key":"8709_CR20","doi-asserted-by":"publisher","first-page":"652674","DOI":"10.3389\/fneur.2021.652674","volume":"12","author":"LP Rybak","year":"2021","unstructured":"Rybak LP, Ramkumar V, Mukherjea D. Ototoxicity of non-aminoglycoside antibiotics. Front Neurol. 2021;12:652674. https:\/\/doi.org\/10.3389\/fneur.2021.652674.","journal-title":"Front Neurol"},{"key":"8709_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/AAC.01088-08","volume":"53","author":"A Forouzesh","year":"2009","unstructured":"Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother. 2009;53:483\u20136. https:\/\/doi.org\/10.1128\/AAC.01088-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"8709_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2471\/BLT.19.230367","volume":"97","author":"BO Olusanya","year":"2019","unstructured":"Olusanya BO, Davis AC, Hoffman HJ. Hearing loss grades and the International classification of functioning, disability and health. Bull World Health Organ. 2019;97:725\u20138. https:\/\/doi.org\/10.2471\/BLT.19.230367. Cited:in: PMID: 31656340.","journal-title":"Bull World Health Organ"},{"key":"8709_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/003655400310000184","volume":"35","author":"O Friberg","year":"2003","unstructured":"Friberg O, Jones I, Sj\u00f6berg L, S\u00f6derquist B, Vikerfors T, K\u00e4llman J. Antibiotic concentrations in serum and wound fluid after local gentamicin or intravenous dicloxacillin prophylaxis in cardiac surgery. Scand J Infect Dis. 2003;35:251\u20134. https:\/\/doi.org\/10.1080\/003655400310000184. Cited:in: PMID: 12839154.","journal-title":"Scand J Infect Dis"},{"key":"8709_CR24","doi-asserted-by":"publisher","first-page":"e02280","DOI":"10.1128\/AAC.02280-18","volume":"63","author":"L Morata","year":"2019","unstructured":"Morata L, Cobo J, Fern\u00e1ndez-Sampedro M, Guisado Vasco P, Ruano E, Lora-Tamayo J, S\u00e1nchez Somolinos M, Gonz\u00e1lez Ruano P, Rico Nieto A, Arnaiz A, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrob Agents Chemother. 2019;63:e02280-e2318. https:\/\/doi.org\/10.1128\/AAC.02280-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"8709_CR25","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.26355\/eurrev_202302_31233","volume":"27","author":"A De Vito","year":"2023","unstructured":"De Vito A, Fiore V, Colpani A, Zauli B, Fanelli C, Tiseo G, Occhineri S, Babudieri S, Falcone M, Madeddu G. The current and future off-label uses of dalbavancin: a narrative review. Eur Rev Med Pharmacol Sci. 2023;27:1222\u201338. https:\/\/doi.org\/10.26355\/eurrev_202302_31233. Cited:in: PMID: 36808371.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"8709_CR26","doi-asserted-by":"publisher","first-page":"106749","DOI":"10.1016\/j.ijantimicag.2023.106749","volume":"61","author":"T Fazili","year":"2023","unstructured":"Fazili T, Bansal E, Garner D, Gomez M, Stornelli N. Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review. Int J Antimicrob Agents. 2023;61:106749. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106749. Cited:in: PMID: 36758775.","journal-title":"Int J Antimicrob Agents"},{"key":"8709_CR27","doi-asserted-by":"publisher","first-page":"ofab486","DOI":"10.1093\/ofid\/ofab486","volume":"8","author":"MM Cooper","year":"2021","unstructured":"Cooper MM, Preslaski CR, Shihadeh KC, Hawkins KL, Jenkins TC. Multiple-dose dalbavancin regimens as the predominant treatment of deep-seated or endovascular infections: a scoping review. Open Forum Infect Dis. 2021;8:ofab486. https:\/\/doi.org\/10.1093\/ofid\/ofab486.","journal-title":"Open Forum Infect Dis"},{"key":"8709_CR28","doi-asserted-by":"publisher","first-page":"783346","DOI":"10.3389\/fncel.2022.783346","volume":"16","author":"Y Yang","year":"2022","unstructured":"Yang Y, Chen X, Tian K, Tian C, Chen L, Mi W, Li Q, Qiu J, Lin Y, Zha D. Heme oxygenase-1 protects hair cells from gentamicin-induced death. Front Cell Neurosci. 2022;16:783346. https:\/\/doi.org\/10.3389\/fncel.2022.783346. Cited:in: PMID: 35496911.","journal-title":"Front Cell Neurosci"},{"key":"8709_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.otc.2021.08.007","volume":"54","author":"PS Steyger","year":"2021","unstructured":"Steyger PS. Mechanisms of ototoxicity and otoprotection. Otolaryngol Clin North Am. 2021;54:1101\u201315. https:\/\/doi.org\/10.1016\/j.otc.2021.08.007. Cited:in: PMID: 34774227.","journal-title":"Otolaryngol Clin North Am"},{"key":"8709_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jgar.2021.03.026","volume":"25","author":"M Matt","year":"2021","unstructured":"Matt M, Duran C, Courjon J, Lotte R, Moing VL, Monnin B, Pavese P, Chavanet P, Khatchatourian L, Tattevin P, et al. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. J Glob Antimicrob Resist. 2021;25:341\u20135. https:\/\/doi.org\/10.1016\/j.jgar.2021.03.026. Cited:in: PMID: 33962065.","journal-title":"J Glob Antimicrob Resist"},{"key":"8709_CR31","doi-asserted-by":"publisher","first-page":"e0224561","DOI":"10.1371\/journal.pone.0224561","volume":"14","author":"C Humphrey","year":"2019","unstructured":"Humphrey C, Veve MP, Walker B, Shorman MA. Long-term vancomycin use had low risk of ototoxicity. PLoS One. 2019;14:e0224561. https:\/\/doi.org\/10.1371\/journal.pone.0224561. Crivellari M, editor.","journal-title":"PLoS One"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08709-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T01:05:15Z","timestamp":1700442315000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08709-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8709"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08709-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"6 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The case report was determined not to require Ethics Committee (EC) review.The patient provided a written informed consent to participate. A copy of the written consent is available upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publishing the personal and clinical details in this case report. A copy of the written consent can be provided upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"706"}}